Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin
2019 Genitourinary Cancers SymposiumStefanie C. Fischer, MD, of Manchester Cancer Research Centre and The Christie NHS Foundation Trust, discusses an international retrospective analysis of the rare clinical scenario of men relapsing after adjuvant treatment with bleomycin/etoposide/cisplatin for clinical stage I nonseminoma (Abstract 510).
Related Videos
Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease
Ignacio Duran, MD, PhD, on Renal Cell Carcinoma: Results From the METEOR Trial on Cabozantinib vs Everolimus
Ignacio Duran, MD, PhD, of the Hospital Universitario Marqués de Valdecilla, discusses an overall survival analysis of the phase III METEOR trial of cabozantinib vs everolimu...
Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Results From the NIVOREN GETUG-AFU 26 Study on Nivolumab
Laurence Albiges, MD, PhD, of Gustave Roussy, discusses findings on the safety and efficacy of nivolumab used in a “real world” prospective study on metastatic renal cell car...
Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?
Craig R. Nichols, MD, on Testicular Cancer Cases: Should They Be Discussed With High-Volume Centers?
Craig R. Nichols, MD, of the Testicular Cancer Commons and the SWOG Group Chair's Office, discusses the superior outcomes obtained at high-volume centers, the impracticality ...
